This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
Top Research Reports for Today: DIS, TXN, LMT
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Texas Instruments (TXN), and Lockheed Martin (LMT).
Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
5 Toxic Stocks to Dump or Play Short to Make Gains
by Zacks Equity Research
Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
by Arpita Dutt
Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
by Arpita Dutt
Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte
by Zacks Equity Research
Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte
5 Toxic Stocks to Abandon or Play Short Right Now
by Zacks Equity Research
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
Biotech ETFs Powered by Q4 Earnings
by Sweta Killa
Improved earnings are driving the biotech space and ETFs higher over the past 10 days.
5 Toxic Stocks to Dump or Play Short for Gains
by Zacks Equity Research
Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.
Top Analyst Reports for Alphabet, Citigroup, Chevron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Chevron (CVX) and Citigroup (C).
Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up
by Zacks Equity Research
Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
by Zacks Equity Research
We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
What Lies in Store for Pfizer (PFE) this Earnings Season?
by Zacks Equity Research
Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review
by Arpita Dutt
There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Why Vertex (VRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Vertex (VRTX) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.
Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.
4 Drug Stocks Poised to Surprise this Earnings Season
by Zacks Equity Research
Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.